AUG 25, 2019 03:43 PM PDT

Comparison of Three Frontline Breast Cancer Drugs

WRITTEN BY: Nouran Amin

Breast cancer affects 250,000 women in the U.S. annually. Those with most common form test positive for hormone receptors (HR+) and negative for the HER2 receptor and can respond well to treatment when diagnosed early. However, women in advanced stages have had few treatment options until the development of CDK4/6 inhibitors.

These drugs were effective in blocking tumor growth and boosting survival rates that the U.S. Food and Drug Administration had fast-tracked their approval. While this class of drugs has the same biological targets, recent research suggests critical differences.

Now, a study published in Cell Chemical Biology, carried out the first comparison of the three currently approved CDK4/6 inhibitors: abemaciclib, palbociclib, and ribociclib.

“Our findings are an important reminder that just because drugs are marketed to have the same nominal targets, it doesn’t mean they are necessarily equally effective in all situations,” says Termeer Fellow Caitlin Mills. “The most common form of breast cancer is hormone receptor-positive, and for CDK4/6 inhibitors, there is the potential to make an enormous difference for a very large number of women by understanding how these drugs could be optimally used.”

The FDA approved palbociclib in 2015, the drug showed promising results in targeting two culprit proteins CDK4 and CDK6. The specificity led to significant improvements in halting disease progression and extending survival. Shortly after, the two other similar drugs--abemaciclib and ribociclib, were approved for patients in advanced stages of HR+/HER2- breast cancer. However, the drugs differed in their chemical structures and patients reported different side effects in patients. The question remained unclear if they were functionally different.

Phases of the moon are used to convey a progressively better understanding of the target spectrum of CDK4/6 inhibitors. Illustration by Lily A. Chylek. Credit: Harvard University

“Despite the sophistication of industrial drug discovery, the activities of many drugs are not fully understood at the time of their approval by the FDA,” said senior study author Peter Sorger, the HMS Otto Krayer Professor of Systems Pharmacology in the HMS Department of Systems Biology and director of the Laboratory of Systems Pharmacology. “In this case, it appears that the drug abemaciclib may unexpectedly work in patients who are not responsive to other drugs in the class.”

In the study, researchers examined the molecular activity of each of the CDK4/6 inhibitors across a variable doses and dosage timings. The profiled the effects of these drugs on cellular growth rate, viability, gene expression and protein activity, and other indicators.

“Characterizing the exact target inhibition profile and the biological effects of these therapeutic agents is essential, because in some instances these differences may explain why one works and why another doesn’t,” said study co-senior author Dejan Juric, director of the Termeer Center. “Thorough and carefully designed studies are the only way to understand how best to sequence or combine these transformative drugs, and to identify which will be most beneficial for any individual patient.”

Source: Harvard Medical School

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 18, 2019
Health & Medicine
SEP 18, 2019
Remember Joe Camel? E-cigarette cartoon ads increase the chances of vaping
Do you remember the infamous "Joe Camel" advertisements for cigarettes back in the 1980s and 90s? These ads successfully got a generation of youn...
SEP 18, 2019
Drug Discovery
SEP 18, 2019
Experimental Drug Encourages Bone Growth in Children with Dwarfism
An experimental drug called vosoritide, alters certain proteins that block bone growth, which allowed the average annual growth of bone in a study of 35 ch...
SEP 18, 2019
Genetics & Genomics
SEP 18, 2019
Combination Therapy Eliminates HIV From Rodent Model
In 2017, 1.8 million new cases of HIV infection were diagnosed around the world, and around 37 million people live with the virus....
SEP 18, 2019
Drug Discovery
SEP 18, 2019
Aspirin Usage Improves Liver Function After Embolization Treatment
Aspirin usage has been under scrutiny in recent research. But now, studies are bringing aspirin therapy in renewed light with its association in improving ...
SEP 18, 2019
Drug Discovery
SEP 18, 2019
How Does Ecstasy Treat PTSD?
Conventionally, Post Traumatic Stress Disorder (PTSD) is treated via talk therapy, with the aim of getting patients to open up about their trauma and rewir...
SEP 18, 2019
Drug Discovery
SEP 18, 2019
Can FDA Approved Ketamine Drug Spravato Really Treat Depression?
President Trump is allegedly in support of a new drug to combat depression. He even urged the Department of Veterans Affairs to purchase it and “get ...
Loading Comments...